Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG

12 Nov 2026 0 comments

Following the release of phase 3 NIMBLE findings, Ali Habib, MD, examines the clinical significance of cemdisiran's MG-ADL results alongside key safety and tolerability considerations.

Source: NeurologyLive Published 12 Nov 2026 Imported 12 Nov 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment